Cargando…
Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
Autores principales: | Boerrigter, Guido, Costello-Boerrigter, Lisa C, Harty, Gail J, Burnett, John C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363203/ http://dx.doi.org/10.1186/1471-2210-11-S1-P11 |
Ejemplares similares
-
The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011) -
Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011) -
Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis
por: Martin, Fernando L, et al.
Publicado: (2011) -
Cardiac Natriuretic Peptides: Contributors to Cardiac Cachexia or Possible Anti-obesity Agents or Both?
por: Costello-Boerrigter, Lisa C.
Publicado: (2012) -
Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community
por: Macheret, Fima, et al.
Publicado: (2009)